Welcome to the arena. This is Galen, Chief Physician of the Gladiators. I’m here to equip you for greatness. Because the sharpest warriors are always up-to-date on the latest advancements in health and longevity. Nobody’s dying anytime soon on my watch.

Today’s Roundup:

1. FDA adds a vision-loss warning to every GLP-1 label

NAION is a rare “eye stroke” from reduced blood flow to the optic nerve that can cause sudden, painless and sometimes permanent vision loss in one eye. Across 126 trials covering 134,253 patients, there were 6.4 cases per 100,000 person-years on GLP-1s vs. 3.8 cases on other drugs or placebo.

  • NAION cases | GLP-1: 10

  • NAION cases | other drugs or placebo: 5

The FDA now requires a warning on all GLP-1 drugs, including Ozempic, Wegovy, Zepbound, Mounjaro, Foundayo, Trulicity, and Victoza, about a potential increased risk of NAION.

The absolute risk for the rare eye-stroke is still small.

released: Mon, 11/09/2026
source: FDA Drug Safety Communication, an official regulatory safety notice

2. Ultra-processed diets linked strongly to blood biomarkers

A study with 6,010 UK adults found the following blood signatures:

Blood signatures of a high ultra-processed food diet

  • High triglycerides ❌

  • High omega-6 to omega-3 ratio (higher inflammatory fats like seed oils, not enough fish fats) ❌

  • High pyruvate & citrate (blood sugar byproducts; linked to eating lots of sugar and refined carbs) ❌

  • Low omega-3s ❌

  • Low HDL ❌

Blood signatures of a minimally processed diet

  • High polyunsaturated fats (healthy fats!) ✅

  • High omega-3s ✅

  • High HDL ✅

  • Lower saturated fat ratio ✅

  • Lower total cholesterol ✅

  • Lower LDL ✅

The ultra-processed diet pattern was linked to 19% higher heart-disease risk and 20% higher T2 diabetes risk, while the minimally processed diet pattern was linked to 19% lower heart disease risk and 40% lower diabetes risk.

released: Wed, 11/04/2026
source: UCL news release on a peer-reviewed prospective cohort study

3. Irregular sleep timing linked to higher heart risk

Researchers analyzed more than 1M nights of sleep from 10,362 adults, none of whom had heart or metabolic disease at the start. The following was discovered

  • People whose bedtimes and wake times bounced around from night to night: 20-23% higher risk of heart attack, stroke, and heart failure

  • Each extra 29 minutes of night-to-night variation in sleep length was linked to a 24% higher risk

Consistency in sleep may play a bigger role in heart health than we previously thought. Circadian rhythm is a true pillar of health.

released: Mon, 11/02/2026
source: American Heart Association press release on a preliminary conference abstract

4. The Wegovy pill (GLP-1) is beating forecasts and expanding the market

Novo Nordisk’s Wegovy pill did $810M in revenue last quarter, well above the forecasted $675M. For context, its main rival pill, Eli Lilly’s Foundayo, made $184M in the same quarter, missing forecasts.

In the week ending Oct 23, the Wegovy pill had ~183,000 prescriptions vs. ~63,000 Foundayo prescriptions. Although Eli Lilly trails significantly in the pill market, they still dominate the injectable market.

Novo’s CEO says about 80% of people starting the Wegovy pill are new to GLP-1s. They’re effectively expanding the market, but why?

  • A pill is a lower barrier-to-entry than a needle for many people

  • Wegovy launched 3 months prior to its rival

  • A relatively “affordable” $149/month

released: Wed, 11/04/2026
source: CNBC, a business news report on Novo Nordisk’s company-reported Q3 earnings

5. Lowering Lp(a) didn’t prevent heart attacks in people with heart disease

Lp(a) is an inherited, cholesterol-like particle in the blood that diet and statins barely change, and high levels have long been tied to heart attacks and strokes.

In a trial with 8,300 people who already had heart disease, a monthly shot called pelacarsen was administered that lowered Lp(a) by ~78%. After a median 4.7 years, major heart events were essentially identical:

  • 12.3% on the drug that lowered Lp(a)

  • 12.1% on placebo

For people who already have heart disease, fixing the blood biomarker Lp(a) does not notably prevent heart attacks.

Given genetics’ strong influence on Lp(a) levels, it is still recommended to get tested once to see where you stand.

released: Sat, 11/07/2026
source: American Heart Association press release on a phase 3 randomized trial published in the New England Journal of Medicine

Take complete agency over your health and longevity

Reply

Avatar

or to participate